化学发光酶免疫法检测血清GP73的临床应用

发布时间：2018-11-24 17:05

【摘要】：目的利用新研发的磁颗粒化学发光法(magnetism particulate chemiluminescence immunoassay,MP-CLIA)替代酶联免疫法(enzyme linked immunosorbent assay,ELISA)检测肝细胞癌(hepatocellular carcinoma,HCC)、肝硬化、病毒性肝炎、自身免疫性肝炎等多种临床样本的血清高尔基体蛋白73(Golgi protein 73,GP73)浓度,进一步探讨MP-CLIA检测血清GP73的临床应用价值。方法采用建立的MP-CLIA法分别检测健康对照者及各种病人血清GP73浓度,并进行分组比较分析。分别计算MP-CLIA和ELISA 2种方法检测GP73诊断HCC的受试者工作特征(receiver operating characteristic,ROC)曲线下面积。测定50例肝硬化病人和69例HCC病人血清GP73和甲胎蛋白(alpha-fetoprotein,AFP)浓度,比较GP73和AFP对HCC的临床诊断效能。同时,对69例HCC病人进行分期比较GP73浓度,对其他良性肝病和其他肿瘤组分别与健康对照组比较分析血清GP73浓度。结果MP-CLIA与ELISA两种方法测定血清GP73在HCC诊断中的ROC曲线下面积差异无统计学意义(P0.05)。肝细胞癌组、肝硬化组和健康对照组的血清GP73浓度差异有统计学意义(P0.05)。肝细胞癌中T1期、T2期、T3期和T4期的血清GP73浓度分别为1.88 nmol/L,2.72 nmol/L,3.22 nmol/L和3.44 nmol/L,早期HCC组与肝硬化组和晚期HCC组比,差异均有统计学意义(P0.05)。自身免疫性肝炎、脂肪肝、病毒性肝炎和HCC高危人群血清GP73浓度与健康对照组相比,差异均有统计学意义(P0.05)。其他肿瘤组的GP73浓度与对照组和HCC组,差异均有统计学意义(P0.05)。结论 MP-CLIA法测定血清GP73结果可靠,GP73是一个HCC早期诊断的血清标志物。
[Abstract]:Objective to detect hepatocellular carcinoma (hepatocellular carcinoma,HCC), liver cirrhosis and viral hepatitis by magnetic particle chemiluminescence (magnetism particulate chemiluminescence immunoassay,MP-CLIA) instead of enzyme linked immunosorbent assay (enzyme linked immunosorbent assay,ELISA). The concentration of Golgi body protein 73 (Golgi protein 73 (GP73) in serum samples of autoimmune hepatitis and other clinical samples was studied to further explore the clinical application value of MP-CLIA in detecting serum GP73. Methods the serum GP73 levels in healthy controls and patients were detected by MP-CLIA method and compared with each other. The area under the curve of MP-CLIA and ELISA were calculated for detecting the operating characteristics of HCC by GP73. Serum GP73 and alpha-fetoprotein (alpha-fetoprotein,AFP) were measured in 50 patients with liver cirrhosis and 69 patients with HCC. The clinical diagnostic efficacy of GP73 and AFP for HCC was compared. At the same time, 69 patients with HCC were compared with GP73 by stages. The serum GP73 levels in other benign liver diseases and other tumor groups were compared with those in healthy controls. Results there was no significant difference in the area under the ROC curve between MP-CLIA and ELISA in the diagnosis of HCC (P0.05). There was significant difference in serum GP73 concentration between HCC group, cirrhosis group and healthy control group (P0.05). The serum GP73 concentrations in T1, T2, T3 and T4 stages of hepatocellular carcinoma were 1.88 nmol/L,2.72 nmol/L,3.22 nmol/L and 3.44 nmol/L, respectively, compared with those in cirrhosis group and late HCC group. The difference was statistically significant (P0.05). The levels of serum GP73 in autoimmune hepatitis fatty liver viral hepatitis and HCC high risk group were significantly higher than those in healthy control group (P0.05). The concentration of GP73 in other tumor groups was significantly different from that in control group and HCC group (P0.05). Conclusion MP-CLIA method is reliable for the determination of serum GP73 and GP73 is a serum marker for early diagnosis of HCC.
【作者单位】：首都医科大学附属北京同仁医院检验科;首都医科大学附属北京同仁医院肝胆外科;首都医科大学附属北京同仁医院消化内科;首都医科大学基础医学院人体解剖与组织胚胎学系;
【基金】：首都临床特色项目(z141107006614007) 首都医科大学科研基金-校自然基金(2015ZR07)~~
【分类号】：R730.43;R735.7

【参考文献】